[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338833-105":59,"doc-detail-338833-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","next-generation-cea-car-nk-92-cells-against-solid-tumors-overcoming-tumor-microenvironment-challenges-in-colorectal-cancer","Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors - Overcoming Tumor Microenvironment Challenges in Colorectal Cancer","","Colorectal carcinoma presents a demanding clinical problem requiring improved therapeutic options. Next-generation chimeric antigen receptor (CAR) natural killer (NK) cell therapy is evaluated as an alternative to CAR T approaches for colorectal cancer. A cell-associated target, carcinoembryonic antigen (CEA), is selected to overcome soluble antigen shedding that can disrupt CAR recognition and trafficking within the tumor microenvironment (TME). The study introduces a PD1 checkpoint inhibitor and CCR4 chemokine receptor–enhanced CAR construct and tests it using 3D multicellular tumor spheroid models.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/next-generation-cea-car-nk-92-cells-against-solid-tumors-overcoming-tumor-microenvironment-challenges-in-colorectal-cancer/338833/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/next-generation-cea-car-nk-92-cells-against-solid-tumors-overcoming-tumor-microenvironment-challenges-in-colorectal-cancer/338833.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is CEA an important target for CAR-NK therapy in colorectal cancer?","Question",{"text":113,"@type":114},"CEA is widely expressed and is involved in tumorigenesis and metastasis. Soluble shedding of CEA can hinder CAR recognition and migration in the TME, so the approach targets cell-associated CEA to improve effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What design features are incorporated into the next-generation CEA-CAR-NK-92 cells?",{"text":118,"@type":114},"The construct targets cell-associated CEA and includes a PD1-checkpoint inhibitor component plus a CCR4 chemokine receptor to enhance homing and infiltration through the tumor microenvironment.",{"name":120,"@type":111,"acceptedAnswer":121},"How was therapeutic activity assessed against colorectal cancer in this work?",{"text":122,"@type":114},"The study tested cytotoxicity against CRC using colorectal cell lines and 3D multicellular tumor spheroid (MCTS) models that emulate key elements of the tumor microenvironment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338833,1790129289,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","cancers   \nArticle  \nNext-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer  \nAlexander Sebastian Franzén 1,2, Abdelhadi Boulifa 1,2, Clarissa Radecke 2, Sebastian Stintzing 2, Martin J. Raftery 1,2 and Gabriele Pecher 1,2, *  \nCitation: Franzén, A.S.; Boulifa, A.; Radecke, C.; Stintzing, S.; Raftery, M.J.; Pecher, G. Next-Generation  \nCEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer. Cancers 2024, 16, 388. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16020388  \nAcademic Editors: Massimo Vitale, Daniel A. Vallera, Simona Sivori and Claudia Cantoni  \nReceived: 4 December 2023  \nRevised: 10 January 2024  \nAccepted: 12 January 2024  \nPublished: 16 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany  \n2 Competence Center of Immuno-Oncology and Translational Cell Therapy (KITZ), Department of Hematology, Oncology and Tumor Immunology, CCM, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany  \n* Correspondence: [gabriele.pecher@charite.de](gabriele.pecher@charite.de); Tel.: +49-30-450-513131  \nSimple Summary: Colon cancer is a solid tumor that is a prominent contributor to global mortality. Immune cells genetically engineered with a chimeric antigen receptor (CAR) that can recognize cancer-specific targets is a new innovative therapy approach that has had success in treating blood cancers but is still in development for treating solid tumors such as colon cancer. Part of the reason for the added difficulty in targeting solid tumors is the tumor microenvironment that acts as a protective barrier around a solid tumor. In this research paper, we have developed a new cellular approach for the targeted treatment of colon cancer that is designed to overcome the tumor microenvironment. We tested this new CAR cell therapy against multiple solid colon cancer models, and confirmed its efficacy and functionality in finding and eliminating solid tumors.  \nAbstract: Colorectal carcinoma (CRC) presents a formidable medical challenge, demanding innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy has emerged as a promising alternative to CAR T-cell therapy for cancer. A suitable tumor antigen target on CRC is carcinoembryonic antigen (CEA), given its widespread expression and role in tumorigenesis and metastasis. CEA is known to be prolifically shed from tumor cells in a soluble form, thus hindering CAR recognition of tumors and migration through the TME. We have developed a nextgeneration CAR construct exclusively targeting cell-associated CEA, incorporating a PD1-checkpoint inhibitor and a CCR4 chemokine receptor to enhance homing and infiltration of the CAR-NK-92 cell line through the TME, and which does not induce fratricidal killing of CAR-NK-92-cells. To evaluate this therapeutic approach, we harnessed intricate 3D multicellular tumor spheroid models (MCTS), which emulate key elements of the TME. Our results demonstrate the effective cytotoxicity of CEA-CAR-NK-92 cells against CRC in colorectal cell lines and MCTS models. Importantly, minimal off-target activity against non-cancerous cell lines underscores the precision of this therapy. Furthermore, the integration of the CCR4 migration receptor augments homing by recognizing target ligands, CCL17 and CCL22 . Notably, our CAR design results in no signific","cbCaidQgDWydawES","https://ap.wps.com/l/cbCaidQgDWydawES","pdf",5538361,"English","# Introduction\n## Natural killer (NK) cell immunotherapy\n## CAR engineering and rationale for CEA targeting\n# Abstract Overview\n## Target selection (CEA) and tumor microenvironment barriers\n## CAR-NK construct design and functional evaluation\n## Experimental models and key outcomes","[{\"question\":\"Why is CEA an important target for CAR-NK therapy in colorectal cancer?\",\"answer\":\"CEA is widely expressed and is involved in tumorigenesis and metastasis. Soluble shedding of CEA can hinder CAR recognition and migration in the TME, so the approach targets cell-associated CEA to improve effectiveness.\"},{\"question\":\"What design features are incorporated into the next-generation CEA-CAR-NK-92 cells?\",\"answer\":\"The construct targets cell-associated CEA and includes a PD1-checkpoint inhibitor component plus a CCR4 chemokine receptor to enhance homing and infiltration through the tumor microenvironment.\"},{\"question\":\"How was therapeutic activity assessed against colorectal cancer in this work?\",\"answer\":\"The study tested cytotoxicity against CRC using colorectal cell lines and 3D multicellular tumor spheroid (MCTS) models that emulate key elements of the tumor microenvironment.\"}]","Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors - Overcoming Tumor Microenvironment Challenges in Colorectal Cancer | PDF",1790026060,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e021413f0128a4ce5cc5533e5ce1263c.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/284329b3484c72154e0a21daa8d66d8f.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7082d5a0e4c9a481160ae5e8ed1828ba.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65d8b11891be11713e903762554443c1.webp",980,1385]